Published by
The Street
The Street
By GlobeNewswire Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022 include initiating Phase 3 clinical study for ketamine to treat Parkinson’s disease (KETLID) ; completing Phase 2 clinical study for ketamine to treat ALS (KETALS) ; completing observational study with ketamine and betaine for depression and pain (KETABET) ; initiating Phase 2 clinical study for ketamine microneedle patch (KETAPATCH) ; and seeking FDA approval for Ketamine Hydrochloride Injection USP product (KETARX) TORONTO, Dec….
